University of Alberta registers Phase 4 lemborexant nocturia trial with Eisai as collaborator
New crossover study will test Eisai's insomnia drug lemborexant against placebo for nighttime urination in adults 65 and older, not yet recruiting.
This week's only update is a newly registered trial examining lemborexant for nocturia, sponsored by an academic institution with Eisai listed as collaborator.
- The study, titled "How Well and Safely Does Lemborexant Work for People Who Wake up at Night to Urinate (LENS)" (NCT07840638), is sponsored by the University of Alberta, with Eisai Inc. listed as a collaborator.1 The trial is a Phase 4, randomized, placebo-controlled crossover study, and its primary objective is to assess the efficacy of Lemborexant compared with placebo in reducing nocturia episodes in older men and women aged 65 and above with bothersome nocturia.1 The record lists an estimated enrollment of 35 participants1 and status is not yet recruiting, with an estimated start date of October 15, 2026.1
Fact check notes
- Imprecise
New crossover study will test Eisai's insomnia drug lemborexant against placebo for nighttime urination in adults 65 and older, not yet recruiting.
Crossover, placebo, age 65+, and not-yet-recruiting status are all confirmed. The characterization of lemborexant as 'Eisai's insomnia drug' is not explicitly stated in the source (though consistent with its known indication) - the source only lists Eisai as a collaborator on the nocturia trial, not as the drug's insomnia-indication holder. - Checker's noteDescribing lemborexant as 'Eisai's insomnia drug' is not directly supported by the source, which only lists Eisai as a trial collaborator; the drug's insomnia indication is not stated in this document.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Where the check questioned a sentence, its note is shown above. Not investment advice.